Collaboration Details

Title of Collaborative Activity:

FDA Blood Products Advisory Committee

Description of Collaborative Activity:

The FDA Blood Products Advisory Committee advises the FDA regarding issues of blood safety and efficacy. The committee reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum, or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases.

Type of Collaborative Activity:

Advisory Group

Year the Collaborative Activity Originated:

2007

NIH Participating Institutes/Centers/Office of the Director:

CC, NHLBI

HHS Agency Collaborators on this Activity:

CDC, FDA